ZURICH, Dec 5 (Reuters) – Roche’s Gazyva cancer drug
did not show a significant overall survival benefit and raised
greater safety concerns than its predecessor Rituxan, a study
showed, raising…
The post Study raises questions over benefit of Roche’s Gazyva cancer drug appeared first on NASDAQ.